Cargando…

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis

BACKGROUND: Severe asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of the best biologic is a matter of debate. Indeed, switching between biologics is c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caruso, Cristiano, Cameli, Paolo, Altieri, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Canonica, Giorgio Walter, Centanni, Stefano, D’Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Caminati, Marco, Vultaggio, Alessandra, Zullo, Alessandro, Rizzoli, Sara, Boarino, Silvia, Vitiello, Gianfranco, Menzella, Francesco, Di Marco, Fabiano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478391/ https://www.ncbi.nlm.nih.gov/pubmed/36117962 http://dx.doi.org/10.3389/fmed.2022.950883

Ejemplares similares

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
por: D'Amato, Maria, et al.
Publicado: (2022)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
por: Vultaggio, Alessandra, et al.
Publicado: (2023)

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study
por: Menzella, Francesco, et al.
Publicado: (2022)

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm(3): A Post Hoc Analysis from the ANANKE Study
por: Senna, Gianenrico, et al.
Publicado: (2022)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
por: Menzella, Francesco, et al.
Publicado: (2021)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
por: Caminati, Marco, et al.
Publicado: (2023)

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
por: Caminati, Marco, et al.
Publicado: (2019)

Ananke: temporal clustering reveals ecological dynamics of microbial communities
por: Hall, Michael W., et al.
Publicado: (2017)

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis
por: Di Bona, Danilo, et al.
Publicado: (2021)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
por: Campisi, Raffaele, et al.
Publicado: (2023)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma
por: Lombardo, Nicola, et al.
Publicado: (2020)

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
por: Pelaia, Corrado, et al.
Publicado: (2018)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
por: Pelaia, Corrado, et al.
Publicado: (2021)

Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting
por: Vitale, Carolina, et al.
Publicado: (2023)

Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?
por: Menzella, Francesco, et al.
Publicado: (2019)

Real world effectiveness of benralizumab on respiratory function and asthma control
por: Menzella, Francesco, et al.
Publicado: (2021)

The ANANKE relative energy gradient (REG) method to automate IQA analysis over configurational change
por: Thacker, Joseph C. R., et al.
Publicado: (2017)

Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”
por: Calzetta, Luigino, et al.
Publicado: (2022)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use
por: Nolasco, Santi, et al.
Publicado: (2020)

Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)

Treatment of Widespread Eosinophilic Cellulitis (Wells’ Syndrome) with Benralizumab
por: BLOMBERG, Maria, et al.
Publicado: (2020)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
por: Pelaia, Corrado, et al.
Publicado: (2021)

Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
por: Vantaggiato, Lorenza, et al.
Publicado: (2022)

Health and social impacts of COPD and the problem of under-diagnosis
por: Carlone, Stefano, et al.
Publicado: (2014)

Successful treatment of eosinophilic cystitis with benralizumab
por: Cooke, W Donald, et al.
Publicado: (2020)

Eosinophilic bronchiolitis successfully treated with benralizumab
por: Sugino, Keishi, et al.
Publicado: (2021)

Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?
por: Ortolani, Claudio, et al.
Publicado: (2020)

Severe refractory asthma: current treatment options and ongoing research
por: Menzella, Francesco, et al.
Publicado: (2018)

COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
por: Renner, Andreas, et al.
Publicado: (2020)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)
por: Canonica, Giorgio Walter, et al.
Publicado: (2020)

Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia
por: Isomoto, Kohsuke, et al.
Publicado: (2020)

Correction to: Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study
por: Scichilone, Nicola, et al.
Publicado: (2019)

Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study
por: Nicola, Scichilone, et al.
Publicado: (2019)

Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of the STORICO Italian Observational Study
por: Blasi, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_su6rhtq935sll33i2673cv2aqq